Rituximab-resistant splenic memory B cells and newly engaged naive B cells fuel relapses in patients with immune thrombocytopenia

Rituximab (RTX), an antibody targeting CD20, is widely used as a first-line therapeutic strategy in B cell–mediated autoimmune diseases. However, a large proportion of patients either do not respond to the treatment or relapse during B cell reconstitution. Here, we characterize the cellular basis re...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Sci Transl Med
Autori principali: Crickx, Etienne, Chappert, Pascal, Sokal, Aurélien, Weller, Sandra, Azzaoui, Imane, Vandenberghe, Alexis, Bonnard, Guillaume, Rossi, Geoffrey, Fadeev, Tatiana, Storck, Sébastien, Fadlallah, Jehane, Meignin, Véronique, Rivière, Etienne, Audia, Sylvain, Godeau, Bertrand, Michel, Marc, Weill, Jean-Claude, Reynaud, Claude-Agnès, Mahévas, Matthieu
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7610758/
https://ncbi.nlm.nih.gov/pubmed/33853929
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.abc3961
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi